Innovotech (TSXV:IOT) Loans Receivable : C$0.00 Mil (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Innovotech Loans Receivable?

Innovotech's Loans Receivable for the quarter that ended in Dec. 2024 was C$0.00 Mil.

Innovotech Loans Receivable Historical Data

The historical data trend for Innovotech's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovotech Loans Receivable Chart

Innovotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Loans Receivable

Get a 7-Day Free Trial

Innovotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Innovotech Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Innovotech Loans Receivable Related Terms

Thank you for viewing the detailed overview of Innovotech's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovotech Inc (TSXV:IOT) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

2011 - 94 Street, Suite L131, Edmonton, AB, CAN, T6N 1H1

Website

https://www.innovotech.ca

Innovotech Inc is a Canada-based company that provides solutions to client biofilm problems through its biofilm contract research department. The core activities of the company are sales of its products, conducting contract research for outside customers, and research and development to identify products for future commercialization. The products of the company include human and fungal biofilm susceptibility tests, a seed treatment designed to combat bacterial and fungal diseases, and an assay used in growing microbial biofilms for research purposes. Geographically, the firm has a business presence in the United States, Canada, and the Rest of the world of which the majority of the revenue is derived from the United States.

Executives

James Gregory Timourian	Senior Officer
Bradley Alan Clark	Director
Alan Clyde Hayes Savage	10% Security Holder
Craig Milne	Director
David Shong-tak Tam	Director
Bernard Grobbelaar	Director